- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Digital Technology: A Double-Edged Sword
Technology offers the promise of engaging patients on a level never seen before.
Technology offers the promise of engaging patients on a level never seen before. The benefits of an engaged patient start with increased compliance-a great thing for pharmaceutical companies-and extend to a more active and empowered consumer of healthcare, and ultimately to better and more affordable outcomes.
But technology is a double-edged sword. Its increasing complexity leads to increasing risk and greater scrutiny.
So what does this mean to Senior Directors and Franchise Leaders at pharmaceutical companies? In this Pharm Exec article, Scott Hansen and Geogg Melick explain why it’s vital to get that technology working right first time.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
